---
title: "PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million"
description: "PTC Therapeutics Inc. forecasts 2026 product revenue between $700 to $800 million, reflecting a 19% to 36% growth year-over-year. The company reported 2025 product and royalty revenue of approximately"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272277820.md"
published_at: "2026-01-12T13:31:21.000Z"
---

# PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million

> PTC Therapeutics Inc. forecasts 2026 product revenue between $700 to $800 million, reflecting a 19% to 36% growth year-over-year. The company reported 2025 product and royalty revenue of approximately $823 million, surpassing previous guidance, with product revenue around $587.8 million. Anticipated R&D and SG&A expenses for 2026 are projected at $775 million to $815 million, or $680 million to $720 million on a non-GAAP basis. PTC holds a strong cash position of about $1.94 billion as of December 31, 2025.

PTC Therapeutics Inc. has released its financial outlook for 2026, projecting total product revenue in the range of $700 to $800 million, which represents a year-over-year growth of 19% to 36%. The company reported unaudited 2025 total product and royalty revenue of approximately $823 million, exceeding its previous guidance. In 2025, product revenue reached around $587.8 million, with Sephience netting approximately $112.1 million since launch. For 2026, PTC anticipates GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses to be between $775 million and $815 million. On a non-GAAP basis, excluding estimated non-cash, stock-based compensation expense, R&D and SG&A expenses are expected to be $680 million to $720 million. The company also reported a strong cash position of about $1.94 billion as of December 31, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY60762) on January 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PTCT.US - PTC Therap](https://longbridge.com/en/quote/PTCT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| PTC Inc. Held Annual Shareholder Meeting | PTC Inc. held its Annual Meeting of Shareholders on February 11, 2026, where shareholders elected eight directors and co | [Link](https://longbridge.com/en/news/275656315.md) |
| Why PTC (PTC) Is Up 9.0% After Raising 2026 Guidance And Accelerating Buybacks | PTC Inc. shares rose 9.0% following the company's first-quarter fiscal 2026 results, which showed increased revenue and  | [Link](https://longbridge.com/en/news/275634000.md) |
| PTC pulls Translarna NDA after unfavourable FDA feedback | PTC Therapeutics has withdrawn its new drug application (NDA) for Translarna, a therapy for Duchenne muscular dystrophy  | [Link](https://longbridge.com/en/news/276067994.md) |
| PTC Therapeutics Withdraws Translarna NDA After FDA Feedback | PTC Therapeutics has withdrawn its New Drug Application for Translarna after FDA feedback indicated insufficient evidenc | [Link](https://longbridge.com/en/news/275818478.md) |
| DarkIris Inc. Publishes 2026 Shareholder Letter Covering Fiscal Year 2025 | DarkIris Inc. has published its 2026 Chairman’s Letter to Shareholders, highlighting key achievements from 2025, includi | [Link](https://longbridge.com/en/news/276130549.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.